

Breast Cancer

An Observational Study of Herceptin SC Safety in Breast Cancer

Trial Status
Completed

Trial Runs In
1 Countries

Trial Identifier
NCT02305628 ML29625

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This is a phase IV, prospective, multicenter, observational study (regulatory post-marketing surveillance) in approximately 600 patients who are to receive Herceptin SC (trastuzumab, subcutaneous administration) per approved local labeling. Patients will be under observation according to standard of care in Korea.

Hoffmann-La Roche
Sponsor

N/A
Phase

NCT02305628 ML29625
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>= 18 Years

Healthy Volunteers
No
